Compare ARDX & FFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARDX | FFC |
|---|---|---|
| Founded | 2007 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 797.8M | 692.3M |
| IPO Year | 2014 | N/A |
| Metric | ARDX | FFC |
|---|---|---|
| Price | $3.02 | $14.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $12.80 | N/A |
| AVG Volume (30 Days) | ★ 4.3M | 245.4K |
| Earning Date | 11-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.79% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,607,000.00 | N/A |
| Revenue This Year | $19.21 | N/A |
| Revenue Next Year | $28.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.96 | $14.26 |
| 52 Week High | $8.40 | $16.95 |
| Indicator | ARDX | FFC |
|---|---|---|
| Relative Strength Index (RSI) | 37.18 | 48.72 |
| Support Level | N/A | $14.32 |
| Resistance Level | $3.35 | $16.34 |
| Average True Range (ATR) | 0.13 | 0.19 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 15.19 | 79.83 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.